UNASSIGNED: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). This study examines and compares the efficiency of AstraZeneca, Sinopharm, and Sputnik vaccines and the correlation of antibody response with age, sex, and history of corona disease in employees of Shahid Beheshti University of Medical Sciences.
UNASSIGNED: 202 participants were included, of which 82 were administered the Astra-Zeneca, 59 were given the Sinopharm, and 61 were given the Sputnik vaccine. SARSCoV-2 IgM and IgG antibody levels were checked four weeks after passing the second dose of all three vaccines using the enzyme-linked immunosorbent assay (ELISA) technique.
UNASSIGNED: There was no significant difference between the amount of IgM and IgG antibodies among three vaccines (p=0.056). For all three vaccines, gender and age did not significantly affect the amount of IgM and IgG antibodies. The history of infection with COVID-19 increased the antibody response (p>0.5).
UNASSIGNED: The titer of IgM and IgG antibodies were not statistically significantly different. The IgM and IgG antibodies produced by vector-based vaccines are higher than the Sinopharm vaccine. Gender did not affect the produced antibody titer. No significant linear relationship was found between age and antibody titer. In people from this study who received two doses of the AstraZeneca vaccine and had a corona history, the average amount of both IgM and IgG antibodies was measured more than the other participants.

BACKGROUND: Studies correlating reactogenicity and immunogenicity of COVID-19 vaccines are limited to BNT162b2, with inconsistent results. We investigated whether adverse reactions after other COVID-19 vaccines reliably predict humoral responses.
METHODS: Adult volunteers were recruited for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca) and/or mRNA (mRNA-1273, Moderna) vaccines administered either 4 or 8 weeks apart. Adverse effects were routinely solicited and recorded by subjects in a standard diary card for up to 84 days post booster vaccination. Anti-SARS-CoV-2 IgG titers were measured pre- (visit 1), and post-booster dose at days 14 (visit 2) and 28 (visit 3).
RESULTS: A total of 399 participants (75% women) with a median age of 41 (interquartile range, 33-48 IQR) years were included. Vaccine-induced antibody titers at days 14 and 28 were significantly higher among subjects who reported local erythema, swelling, pain, as well as systemic fever, chills, headache, myalgia, arthralgia, fatigue compared to those who did not experience local or systemic reactogenicity. Post-vaccination humoral responses did not correlate with the occurrence of skin rash and correlated weakly with gastrointestinal symptoms. A significant correlation between post-vaccination peak body temperature and anti-SARS-CoV-2 spike IgG at Day 14, independent of vaccine type and schedule, was found.
CONCLUSIONS: Specific symptoms of reactogenicity such as post-vaccination injection site pain, swelling, erythema and fever, myalgia and fatigue are significantly predictive of the magnitude of the anti-SARS-CoV-2 antibody response.

The scientific communication landscape has undergone a significant disruption since the COVID-19 pandemic: a huge number of publications, ample use of preprint publications, a fast-spreading digitalized information. This reflected the unprecedented speed of the research on disease and vaccines. Two kinds of infodemic blew up very soon: a scientific and a tabloid one. With knowledge evolving continuously, governments and institutions deployed their communication campaigns very quickly to explain the different measures, including the vaccination strategies and to fight against infodemics. The need for a more focused population, the French-speaking community, arose spontaneously in Israel, leading to the creation of a Vaccine Task Force, independent, multidisciplinary, and composed of 20 high-level volunteers, physicians, pharmacists, and scientists, which provides evidence-based information, open and free, to healthcare professionals and the public, both most in demand, and then the experts\' meetings in Israel and abroad. Current resources: 40 webinars, all recorded and accessible on the association website, questions and answers, press and scientific literature review, and hotline; communication through the website, social media, and audio-visual media. In French, English, and Hebrew. The team undertook to explain the role of Israel in vaccine rollout and real-world data provision to the international community, both in Israel and abroad. Performance indicators are as follow: attendees\' number (~3000), website frequentation (7200 +) social media followers. In conclusion, this information campaign requires no budget; relies on volunteers who expressed their willingness to contribute to the global effort, as seen all over the world; and uses simple, cheap, and ubiquitous IT platforms. The Task Force created ERANIM, the Israel Society for Medication and Vaccines Safety. This scheme could easily apply for minorities or for medium/low-income countries, using the resources available in WHO, Vaccine Safety Net, health agencies, and academies. Key factors are multidisciplinary, influencers belonging to communities, and a network of partnerships.
UNASSIGNED: Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience Background: The scientific communication landscape has undergone a significant disruption since the COVID-19 pandemic: a huge number of publications, ample use of preprint publications, a fast-spreading digitalized information. This reflected the unprecedented speed of the research on disease and vaccines. Two kinds of infodemic blew up very soon: a scientific and a tabloid one. With knowledge evolving continuously, governments and institutions deployed their communication campaigns very quickly to explain the different measures, including the vaccination strategies and to fight against infodemics.An Israelian initiative: method: The need for a more focused population, the French-speaking community, arose spontaneously in Israel, leading to the creation of a Vaccine Task Force, independent, multidisciplinary, and composed of 20 high-level volunteers, physicians, pharmacists, and scientists, which provides science-based information, open and free, to healthcare professionals and the public, both most in demand, and then the experts\' meetings in Israel and abroad.Results: Current resources: More than 40 webinars, recorded, questions and answers, press and scientific literature review, and hotline, through the website, social media, and audio-visual media. In French, English, and Hebrew. The team undertook to explain the role of Israel in vaccine rollout and real-world data provision to the international community, both in Israel and abroad. Performance indicators are as follow: attendees number (~3000), website frequentation (7200 +) social media followers.In conclusion: This information campaign requires no budget; relies on volunteers who expressed their willingness to contribute to the global effort, as seen all over the world; and uses simple, cheap, and ubiquitous IT platforms. The Task Force created ERANIM, the Israel Society for Medication and Vaccines Safety. This scheme could easily apply for minorities or for medium/low-income countries, using the resources available in WHO, Vaccine Safety Net, health agencies, and academies. Key factors are multidisciplinary, influencers belonging to communities, and a network of partnerships.

Erythema nodosum (EN) is a common panniculitis characterized by tender erythematous nodules predominantly on the pretibial area and represents a hypersensitivity reaction to multiple triggers. COVID19 infection and vaccination have been associated with EN in the adult population. We report a pediatric case of EN following COVID19 infection and review the literature on COVID19 infection and COVID19 immunization-related EN.